Drug
Xp23829 QD
Xp23829 QD: highest development phase Phase 2, developed by Dr. Reddy's. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Dr. Reddy's
Trials
| Drug | Phase | Indication |
|---|---|---|
| XP23829 400 mg QD NCT02173301 | Phase 2 | Psoriasis |
Latest
No recent events.
Follow Xp23829 QD on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.